

For Information Contact:
P. Quake Pletcher, Executive Director
317.921.2050
ppletche@iupui.edu

For Immediate Release

**HOOSIER ONCOLOGY GROUP TO UNDERTAKE US CLINICAL
TRIAL OF BNC105 IN RENAL CELL CANCER**

(Indianapolis, IN) -- The **Hoosier Oncology Group (HOG)**, a non-profit, community based, clinical research organization located in Indianapolis, IN, is pleased to announce that it will partner with **Bionomics Limited**, a South Australia based drug discovery and development engine room focused on new treatments for cancer, to evaluate the efficacy of BNC105, its novel vascular disrupting agent (VDA) for the treatment of solid tumor types, in a US clinical trial for a type of kidney cancer known as renal cell carcinoma.

Dr. Nasser Hanna, Chairman of the HOG and Associate Professor at the IU Simon Cancer Center, said, "The Hoosier Oncology Group is enthusiastic to bring potentially innovative treatments to its members and patients, and Bionomics' is a welcomed partner in that pursuit with its novel compound."

Quake Pletcher, Executive Director of the HOG stated, "The HOG continues to serve patients across the state of Indiana so when they seek the best treatment option available with their local oncologist, they can do so near the comfort of their own home and with the support of family and friends."

The HOG has put the "life" in life sciences for 25 years of by putting some of the best cancer research treatment options developed at the IU Simon Cancer Center and their academic partners into community clinics throughout Indiana and beyond. Though based primarily in Indiana, HOG has global reach, partners, and impact. "Bionomics is delighted to be working with an internationally and highly regarded group such as the HOG as we progress the development of BNC105 for the treatment of renal cell cancer," said Chief Executive Officer and Managing Director of Bionomics, Dr Deborah Rathjen. "It provides the clinical reach to recruit suitable patients within a reasonable timeframe and the expertise to manage the type of multicenter trial that will be required."

“The partnership between the Hoosier Oncology Group and Australia’s Bionomics Limited underscores Indiana’s position as a global leader in life sciences and is further proof of our state’s ability to deliver the latest in healthcare-related developments to all corners of the world,” said Mitch Roob, Indiana Secretary of Commerce and chief executive officer of the Indiana Economic Development Corporation. The IEDC’s Australia office assisted in the development of this partnership.

Renal cancer accounts for 2-3% of human malignancies and accounts for 85% of kidney cancers. Every year, approximately 200,000 cases are diagnosed worldwide, with 55,000 people diagnosed in the USA. The five year survival rate for patients with metastatic disease is less than 2%. Kidney cancer is asymptomatic, and in 40% of cases is diagnosed at an advanced stage.

###